Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388 Collaboration will complement Roche's ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

Roche expects filing for up to three new molecular entities in 2026, and accelerating its pipeline through partnerships and ...

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF). Under the ...

Combining petrelintide with Roche's dual GLP-1/GIP receptor agonist CT-388 will further strengthen Roche's pipeline in cardiovascular, renal, and metabolic (CVRM) diseases. As a part of the agreement, ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in combination with two established medicines, new survival data from the ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...